About Cyxone

Cyxone develops new innovative therapies for the treatment of rheumatoid arthritis and multiple sclerosis. Our goal is to improve the quality of life for patients in need of a more effective, convenient and safe treatment option.

Our Drug Projects

Rheumatoid Arthritis (rabeximod)

A unique mechanism-of-action combined with a convenient oral administration and a beneficial tolerability profile

Multiple sclerosis (T20K)

Acts to stop or slow down the progression of multiple sclerosis

Our mission is to provide better therapies for patients suffering from autoimmune diseases

Press Releases

Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor

November 20, 2023 09:22 (CET)
Interim Report 1 January to 30 September 2023

October 27, 2023 08:29 (CEST)

Regulatory
Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K

October 9, 2023 08:38 (CEST)

Regulatory

About Cyxone

Our Drug Projects

Rheumatoid Arthritis (rabeximod)

Multiple sclerosis (T20K)

Press Releases

Cyxone welcomes a renewed engagement by Professor Rikard Holmdahl as Scientific Advisor

Interim Report 1 January to 30 September 2023

Cyxone receives Intention to Grant from the European Patent Office for a unitary patent of T20K

Subscribe to Press Releases